When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

For many, the city of Hanoi is a gateway to northern Vietnam’s great adventures—the emerald islets of Ha Long Bay, the terraced hills of Sapa, the karst valleys of Ninh Bình—but it's well worth ...

Tower of Fantasy is one of several gacha MMOs to enter the space a few years ago. It offers players a Genshin-like experience, but a more focused experience on MMO-like instanced and world boss events ...

The developers of Tower of Fantasy had a live Q&A in which they detailed the new Warp servers. Announced a few months ago, the Warp servers will gut Tower of Fantasy’s gacha mechanics, and brings back ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

A Ukrainian adoptee wept in court as his lawyer detailed his troubled life before he allegedly slaughtered his “caring” American parents. Dima Tower’s audible sobs filled the courtroom in Sarasota, ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...